Neurizon Therapeutics Limited

NUZ

AU0000357261

Pharmaceuticals

Delayed Australian S.E. Other stock markets 08:15:56 09/07/2025 am IST			5-day change	1st Jan Change
0.1650 ^AUD	+6.45%		+3.12%	-2.94%

03/07	Elanco Animal Health Enters Into Licensing Agreement With Neurizon for Monepantel	MT
02/07	Neurizon Therapeutics Secures License Deal With Animal Health Company; Shares Up 3%	MT

PharmAust advances monepantel for motor neurone disease towards FDA approval

Published on 28/02/2024 at 21:20, updated on 28/02/2024 at 21:21

(via NewsDirect)

PharmAust Limited (ASX:PAA) CEO Dr Michael Thurn tells Proactive's Stephen Gunnion that the company had a "pivotal" Pre-Investigational New Drug Application (Pre-IND) meeting with the US Food and Drug Administration (FDA) as it advances the development of monepantel, an approved veterinary drug, for motor neurone disease. Thurn highlighted the drug's potential in exploiting autophagy properties to treat motor neurone diseases by breaking down toxic protein build-ups, particularly TDP-43 aggregates in neurons. The company has completed a Phase 1 oncology clinical study for monepantel in humans and is preparing for a pivotal field trial in dogs for B cell lymphoma. A significant milestone is the upcoming end of Phase 1 for its motor neurone disease program, with data expected by the end of February. Thurn said the FDA's positive feedback indicates the potential for full approval after a 48-week study. Monepantel's mechanism, inducing autophagy, positions it as a promising treatment for various neurodegenerative diseases beyond motor neurone disease, including Alzheimer's and Parkinson's, suggesting its potential as a blockbuster drug.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Latest news about Neurizon Therapeutics Limited

Elanco Animal Health Enters Into Licensing Agreement With Neurizon for Monepantel	03/07	MT
Neurizon Therapeutics Secures License Deal With Animal Health Company; Shares Up 3%	02/07	MT
Neurizon Therapeutics Develops Oral Liquid Formulation for Amyotrophic Lateral Sclerosis Drug Candidate	26/06	MT
Neurizon Therapeutics Says High Levels of NUZ-001 Drug Candidate Cross Blood-Brain Barrier in Rodent Study	20/06	MT
NUZ-001 Shows Promise In Zebrafish Model Of Huntington's Disease	16/06	RE
Neurizon® Therapeutics Limited Announces New Preclinical Data Demonstrating Significant Neuroprotective Effects of Nuz-001 Sulfone	16/06	CI
Neurizon Therapeutics Limited Announces Change of Registered Office and Principal Place of Business Address	02/06	CI
Neurizon Reports No Adverse Events as Final Patient Completes Sclerosis Drug Trial; Shares Fall 4%	05/05	MT
Neurizon Therapeutics Appoints Don O'Connell as Chief Financial Officer; Shares Down 4%	22/04	MT
Neurizon Therapeutics Appoints Dan O'Connell As CFO	22/04	RE
Neurizon Therapeutics Limited Appoints Dan O'Connell as Chief Financial Officer	22/04	CI
Neurizon Therapeutics Makes Three Executive Appointments; Shares Up 15%	17/04	MT
Neurizon Therapeutics Completes Study of Drug Candidate on Mouse Motor Neuron Cell Line	04/04	MT
Neurizon Therapeutics Limited Announces Results from an Additional Independent Study Carried Out in Partnership with the University of Queensland	04/04	CI
Neurizon Therapeutics Limited Announces Results from an Independent Study Conducted in Collaboration with Tessara Therapeutics	01/04	CI
ASX Biggest Gainers	28/03	MT
Neurizon Therapeutics Limited(ASX:NUZ) dropped from S&P/ASX Emerging Companies Index	24/03	CI
Neurizon Therapeutics Limited Provides Update on Preparation for Entry into the Healey & AMG Center	24/03	CI
Neurizon Therapeutics Moves to Lift FDA Suspension on NUZ-001 Drug Candidate with Two Studies; Shares Fall 5%	17/03	MT
Neurizon Therapeutics Logs HY Loss Attributable A$7.3 Mln	17/02	RE
Neurizon Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2024	17/02	CI
Neurizon Therapeutics Says Got Guidance From FDA Placing IND Application For NUZ-001 Under Clinical Hold	17/02	RE
Neurizon Gets US Patent for Cancer Drug Candidate; Shares Up 16%	05/02	MT
Neurizon Therapeutics Says US Patent Granted For NUZ-001	05/02	RE
Neurizon Therapeutics Says FDA Places its Investigational New Drug Application on Hold; Shares Hit New 52-Week Low	17/01	MT

Chart Neurizon Therapeutics Limited

Duration

Period

NUZ: Dynamic Chart

Company Profile

Neurizon Therapeutics Ltd, formerly PharmAust Limited, is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. The Company is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.

Employees

Sector

Pharmaceuticals

Calendar

29/08 - Q4 2025 Earnings Release (Projected)

More about the company